HBMK — Hubei Minkang Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Hubei Minkang Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2010 March 31st	2011 March 31st	C2011 December 31st	2012 December 31st	2013 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	12.6	13.9	14.7
Cost of Revenue
Gross Profit	—	—	6	6.76	6.29
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Operating Interest Expense / Income
Unusual Expense / Income
Total Operating Expenses	1.75	0.715	11.9	12.8	14.5
Operating Profit	-1.75	-0.715	0.624	1.15	0.222
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.83	-0.769	-0.066	0.955	0.073
Provision for Income Taxes
Net Income After Taxes	-1.83	-0.769	-0.214	0.961	0.127
Net Income Before Extraordinary Items
Net Income	-1.83	-0.769	-0.214	0.961	0.127
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-1.83	-0.769	-0.214	0.961	0.127
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.023	-0.016	-0.006	0.02	0
Dividends per Share